Cladribine and cytarabine in children refractory high risk multisystem Langerhans cell histiocytosis

There is no uniform regimen for refractory Langerhans cell histiocytosis (LCH). We retrospectively described patients with refractory multisystem and risk organ involvement LCH treated with the low-dose (Ara-c, 100 mg/m(2)/d × 5day; 2-CDA, 5 mg/m(2)/d × 5day) chemotherapy (LDC) and the intermediate-...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wenqian, Ge, Jian, Ma, Honghao, Lian, Hongyun, Cui, Lei, Zhao, Yunze, Li, Zhigang, Wang, Tianyou, Zhang, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481182/
https://www.ncbi.nlm.nih.gov/pubmed/37681174
http://dx.doi.org/10.1016/j.heliyon.2023.e19277

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10481182/
https://www.ncbi.nlm.nih.gov/pubmed/37681174
http://dx.doi.org/10.1016/j.heliyon.2023.e19277

Ejemplares similares